Home Newsfeeds Needham Maintains Buy on Harmonic, Raises Price Target to $19

Needham Maintains Buy on Harmonic, Raises Price Target to $19

Needham analyst Ryan Koontz maintains Harmonic (NASDAQ:HLIT) with a Buy and raises the price target from $17 to $19.

byBenzinga Newsdesk

January 24, 2023

1 minute read

Needham analyst Ryan Koontz maintains Harmonic (NASDAQ:HLIT) with a Buy and raises the price target from $17 to $19.

Media
News

Snap Monetizes AR Capabilities With AR Enterprise Services Launch

By Anusuya Lahiri

March 23, 11:35 AM

Snap Inc (NYSE:SNAP) today launched AR Enterprise Services (ARES), a new enterprise solution to enable businesses to integrate Snap’s…

SNAP

60 Degrees Pharmaceuticals Outlines Plans For Rare Tick-Borne Infection Trial Evaluating Its Malaria Drug

By Vandana Singh

January 22, 2:45 PM

60P Pharmaceuticals advances pivotal study of tafenoquine in hospitalized babesiosis patients after FDA meeting.

SXTP

Verano Q3 Revenue Grows To $240M, Raises Free Cash Flow Guidance, ‘Encouraged’ By Cannabis Reform Developments

By Nina Zdinjak

November 8, 9:25 AM

Chicago-based cannabis company Verano Holdings Corp. (NEO: VRNO) (OTCQX: VRNOF) reported its financial results on Wednesday for the third quarter with revenue of $240.09 million, compared to $234.12 million in the previous quarter.

VRNOF

Analyst Ratings

What 15 Analyst Ratings Have To Say About Neurocrine Biosciences

By Benzinga Insights

April 17, 1:01 PM

Over the past 3 months, 15 analysts have published their opinion on Neurocrine Biosciences (NASDAQ:NBIX) stock. These analysts…

NBIX

Needham Maintains Buy on Harmonic, Raises Price Target to $19

Related Posts

Snap Monetizes AR Capabilities With AR Enterprise Services Launch

60 Degrees Pharmaceuticals Outlines Plans For Rare Tick-Borne Infection Trial Evaluating Its Malaria Drug

Verano Q3 Revenue Grows To $240M, Raises Free Cash Flow Guidance, ‘Encouraged’ By Cannabis Reform Developments

What 15 Analyst Ratings Have To Say About Neurocrine Biosciences